Overview

Buspirone Treatment for Marijuana Dependence

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buspirone